These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8786640)
1. Cholecystokinin-A specific antagonism of KSG-504 to cholecystokinin receptor binding and pancreatic secretion in mammals. Yamazaki Y; Shinagawa K; Takeda H; Kobayashi M; Akahane M; Ajisawa Y Jpn J Pharmacol; 1995 Dec; 69(4):367-73. PubMed ID: 8786640 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist. Yamazaki Y; Akahane M; Kobayashi M; Kitazawa M; Kurashina Y; Iizuka K Jpn J Pharmacol; 1993 Oct; 63(2):219-25. PubMed ID: 7506805 [TBL] [Abstract][Full Text] [Related]
3. Effects of KSG-504, a new cholecystokinin-A-receptor antagonist, on pancreatic exocrine and endocrine secretions in rats. Yamazaki Y; Akahane M; Kobayashi M; Takeda H; Ajisawa Y Jpn J Pharmacol; 1996 Feb; 70(2):183-90. PubMed ID: 8866756 [TBL] [Abstract][Full Text] [Related]
4. [Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions]. Yamazaki Y; Akahane M; Kobayashi M; Shinagawa K; Sugiura M; Ajisawa Y Nihon Yakurigaku Zasshi; 1996 Jan; 107(1):33-44. PubMed ID: 8720296 [TBL] [Abstract][Full Text] [Related]
5. Different inhibitory effects of the newly developed CCK receptor antagonists FK480 and KSG-504 on pancreatic exocrine and endocrine secretion in the isolated perfused rat pancreas. Kihara Y; Otsuki M Pancreas; 1995 Mar; 10(2):109-17. PubMed ID: 7716133 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini. Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413 [TBL] [Abstract][Full Text] [Related]
8. Derivatives of CCK-(26-32) as cholecystokinin receptor antagonists in guinea pig pancreatic acini. Gardner JD; Knight M; Sutliff VE; Tamminga CA; Jensen RT Am J Physiol; 1984 Mar; 246(3 Pt 1):G292-5. PubMed ID: 6199984 [TBL] [Abstract][Full Text] [Related]
9. Characterization of gastrin receptors on guinea pig pancreatic acini. Yu DH; Noguchi M; Zhou ZC; Villanueva ML; Gardner JD; Jensen RT Am J Physiol; 1987 Dec; 253(6 Pt 1):G793-801. PubMed ID: 2447788 [TBL] [Abstract][Full Text] [Related]
10. A new CCK-A antagonist, KSG-504, administered intraduodenally, inhibits pancreatic secretion in rats. Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S Pancreas; 1994 Mar; 9(2):225-9. PubMed ID: 8190724 [TBL] [Abstract][Full Text] [Related]
11. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice]. Kobayashi M; Shinagawa K; Sugiura M; Nagasawa T; Akahane M; Ajisawa Y Nihon Yakurigaku Zasshi; 1996 Apr; 107(4):183-95. PubMed ID: 8690301 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist. Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Taniguchi H; Yazaki N; Endo T; Nagasaki M Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597 [TBL] [Abstract][Full Text] [Related]
14. [Behavioral studies of KSG-504, a new CCK-A receptor antagonist]. Yamazaki Y; Takeda H; Akahane M; Tsubaki A; Ajisawa Y Nihon Yakurigaku Zasshi; 1996 Jan; 107(1):21-31. PubMed ID: 8720295 [TBL] [Abstract][Full Text] [Related]
15. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini]. Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851 [TBL] [Abstract][Full Text] [Related]
16. Amylase secretion from dispersed human pancreatic acini: neither cholecystokinin a nor cholecystokinin B receptors mediate amylase secretion in vitro. Miyasaka K; Shinozaki H; Jimi A; Funakoshi A Pancreas; 2002 Aug; 25(2):161-5. PubMed ID: 12142739 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Talkad VD; Patto RJ; Metz DC; Turner RJ; Fortune KP; Bhat ST; Gardner JD Biochim Biophys Acta; 1994 Oct; 1224(1):103-16. PubMed ID: 7524683 [TBL] [Abstract][Full Text] [Related]
18. Carbachol acts through protein kinase C to modulate cholecystokinin receptors on pancreatic acini. Louie DS; Chung OY Am J Physiol; 1991 Dec; 261(6 Pt 1):G981-6. PubMed ID: 1722647 [TBL] [Abstract][Full Text] [Related]
19. N-terminal fragments of CCK-(26-33) as cholecystokinin receptor antagonists in guinea pig pancreatic acini. Gardner JD; Knight M; Sutliff VE; Jensen RT Am J Physiol; 1985 Jan; 248(1 Pt 1):G98-102. PubMed ID: 2578257 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells. Moon SJ; An JM; Kim J; Lee SI; Ahn W; Kim KH; Seo JT Eur J Pharmacol; 2004 Nov; 505(1-3):61-6. PubMed ID: 15556137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]